Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.
Click here to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by
Specialists assess the pros and cons of using immunotherapy in managing metastatic non–small cell lung cancer and delve into dosage variations and considerations when choosing different immunotherapy types.
Panelists discuss balancing aggressive treatment strategies and maintaining the patient’s quality of life.